Compare BUSE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUSE | AGIO |
|---|---|---|
| Founded | 1868 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 1996 | 2013 |
| Metric | BUSE | AGIO |
|---|---|---|
| Price | $26.61 | $27.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $27.17 | ★ $38.88 |
| AVG Volume (30 Days) | 450.0K | ★ 1.3M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.04% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $719,584,000.00 | $43,011,000.00 |
| Revenue This Year | $23.84 | $76.75 |
| Revenue Next Year | $3.82 | $170.73 |
| P/E Ratio | $17.83 | ★ N/A |
| Revenue Growth | ★ 55.66 | N/A |
| 52 Week Low | $21.41 | $22.24 |
| 52 Week High | $27.65 | $46.00 |
| Indicator | BUSE | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.01 | 43.00 |
| Support Level | $23.57 | $26.03 |
| Resistance Level | $27.31 | $29.69 |
| Average True Range (ATR) | 0.60 | 1.36 |
| MACD | -0.05 | -0.19 |
| Stochastic Oscillator | 57.05 | 25.72 |
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.